A new study published in JAMA Internal Medicine examines the association between the initiation of cholesterol-lowering statin drug treatment and the progression of diabetes. Examining the medical records of 83,022 matched pairs of patients, the researchers found that use of statins was associated with significant progression of the disease. The finding adds to the already weighty pile of scientific evidence attesting to the dangerous nature of these drugs.
Carried out by researchers from the United States, the study examined 12 years of data covering the period 2003-2015. The patients analyzed were 30 years of age or older and had all been diagnosed with diabetes during the study period. The researchers found that, compared to non-users, patients taking statins had a higher likelihood of insulin treatment initiation, developing significant hyperglycemia, experiencing acute glycemic complications, and being prescribed an increased number of glucose-lowering medication classes.
Interestingly, in a finding that further undermines the credibility of the pharmaceutical industry’s cholesterol-lowering dogma, a dose-response relationship was also noted. The researchers discovered that intensively reducing low-density lipoprotein (LDL) cholesterol was associated with the greatest risk of diabetes progression.
The JAMA Internal Medicine study is hardly the first to link statins with diabetes. Nor are the dangers solely confined to patients who have already been diagnosed with the disease. Research published in 2019 found that taking statins more than doubles the likelihood of developing diabetes. Patients using the drugs for more than two years were shown to have over three times the risk.
Other studies show statins increase the risk of developing muscle pain, fatigue, cognitive impairment, and peripheral nerve damage. They are also associated with an increased risk of breast, prostate, lung, and other cancers. A comprehensive review of the scientific literature published in 2008 confirmed many of these links and noted additional associations with heart problems, strokes, sexual dysfunction, thyroid problems, kidney disease, behavioral disorders, neurodegenerative disease, Parkinson’s disease, autoimmune diseases, pancreatic problems, liver disease, skin problems, gastrointestinal problems, psychiatric problems, sleep problems, and other negative effects on health.
Furthermore, an Australian study published in 2018 linked statins to a significantly increased risk of idiopathic inflammatory myositis, a serious muscle disease that can lead to permanent disability and death. Patients with the condition were found to be almost twice as likely to have been taking statins compared to similar individuals from the general population.
Through causing numerous additional health problems that inevitably result in the prescribing of further drugs, statins produce countless billions of dollars of add-on pharmaceutical revenue. Capturing patients in this way – and turning them into repeat customers – is one of the key business strategies of the drug industry and a major driver behind what has become known as ‘polypharmacy’. Research shows that, particularly in older people, taking multiple pharmaceutical drugs results in a significantly greater risk of frailty, disability, and death.
The bottom line here is that the prescribing of multiple drugs to patients is not, and never will be, the answer to achieving optimum health. Were this the case, today’s major chronic diseases would already by now have been eradicated. Instead, patients are misled on an almost daily basis by mainstream media headlines promoting ‘wonder’ and ‘miracle’ drugs. Far from solving the world’s health problems, such headlines simply function as advertisements for the pharmaceutical industry and its multibillion-dollar drug merchandize. Worse still, they also bring false hope to patients.
The greatest threat to the statin drug business today is the discovery by Dr. Matthias Rath that, contrary to what the world has been led to believe, cholesterol is not the cause of heart disease. In a groundbreaking study published in 2015, a team of scientists from the Dr. Rath Research Institute in California demonstrated that, in reality, heart disease is an early form of the vitamin C deficiency disease scurvy. The depositing of cholesterol, lipoproteins, and other blood risk factors in the arteries only occurs when the body has an insufficient supply of vitamin C to maintain their structural integrity.
The fact that the mainstream media hasn’t told us the truth about cholesterol is no accident – it is a direct reflection of the fact that its pharmaceutical industry advertising clients stand to lose billions of dollars in drug sales if we find out about it. It is no exaggeration to say that millions of lives depend on us overcoming this information block.